Date post: | 08-Apr-2018 |
Category: |
Documents |
Upload: | narsimhamusunuri |
View: | 226 times |
Download: | 0 times |
of 31
8/7/2019 durga ganesh 2011
1/31
welcome
8/7/2019 durga ganesh 2011
2/31
Symbol&tagline
8/7/2019 durga ganesh 2011
3/31
history
Kallam Anji Reddy (born 1940) is an Indian entrepreneur inthe pharmaceutical industry,
the founder-chairman ofDr Reddy's Labs, which he established in
1984,
chairman of Dr Reddys Foundation (DRF), the corporate social
responsibility arm of the group, established 1996.[1][2]
8/7/2019 durga ganesh 2011
4/31
Kallam Anji Reddy
Born 1940
Tadepalli, Guntur district
Nationality Indian
Occupation Chairman, Dr Reddy's Labs
8/7/2019 durga ganesh 2011
5/31
Early life and education
He spent his early years in the village ofTadepalli nearGunturin Guntur
District, where his father grew turmeric.
Reddy graduated from the local high school and went on to get his first
Bachelor of science degree fromA.C. College at Gunturin 1958.[3]
Thereafter he, did his B.Sc.-Tech in Pharmaceuticals and Fine chemicals
from Bombay University followed by a Ph.D. in chemical engineering from
the National Chemical Laboratory, Pune in 1969.[4]
8/7/2019 durga ganesh 2011
6/31
Social causes
Naandi Foundation, a not-for-profit development institution that
strives for eradication of poverty has Dr Reddy as its founding
father.
He is also founder-chairman of Dr Reddys Foundation forHumanand Social Development, a social arm of Dr. Reddys Labs
8/7/2019 durga ganesh 2011
7/31
Principal Competitors: RPG Enterprises; GlaxoSmithKline
ConsumerH
ealthcare Ltd.;
East India Pharmaceutical Works Ltd.; Cipla Ltd.;
Concept Pharmaceuticals Ltd.
;
Khandelwal Laboratories Ltd.
;
Dabur India Ltd.
8/7/2019 durga ganesh 2011
8/31
Vision and Mission
by Global Report Initiative G3, covering social, ethical,
economic, nvironmental aspects of our business.
At Dr. Reddys, sustainability is a multi-dimensional
aspiration.
which has its roots in the very purpose of our existence
providing affordable medicines to people around the world
and meeting unmet medical needs through innovation.
8/7/2019 durga ganesh 2011
9/31
Objectives
Discuss with senior management, the Companys Enterprise Risk
Management.
and provide oversight as may be needed;
- Ensure it is apprised of the most significant risks along with the
action management is
taking and how it is ensuring effective ERM;
- Reviewing risk disclosure statements in any public documents or
disclosures.
8/7/2019 durga ganesh 2011
10/31
Role of Board of directors
Dr. Reddys Board of Directors
comprises eminent individuals from
diverse fields
Directors are experts in the diverse
fields of medicine,
And chemistry and medical research
human resource development,
business strategy, finance, and
economicsDr. K.anjireddy
chairman
8/7/2019 durga ganesh 2011
11/31
Top products
Nise
Omez Stamlo
Stamlo beta
Atocor
Omez_z Razo
Enam
8/7/2019 durga ganesh 2011
12/31
Shareholding Pattern on March 31, 2011
PROMOTERS HOLDING:No. of
Shares% of Shares
Individuals 4,289,484 2.53
Companies 39,128,328 23.12
Sub Total 43,417,812 25.65
Indian Financial
Institutions13,863,468 8.19
Banks 400,722 0.24
Mutual Funds 9,451,142 5.58
Sub Total 23,715,332 14.01
8/7/2019 durga ganesh 2011
13/31
8/7/2019 durga ganesh 2011
14/31
Head Quarters & branches
Rest of the World India
North America
Russia and CIS
Europe Source: Evalueserve
7-1-27, AmeerpetHyderabad, 500 016
India
8/7/2019 durga ganesh 2011
15/31
Mile Stones
Announces strategic alliance with GlaxoSmithKline plc to develop.
and market select products across emerging markets outside India
.
Receives approval for Three INDs.
Reorganizes Drug Discovery Operations to merge into Aurigene, a wholly
owned independent subsidiary of Dr. Reddy's
8/7/2019 durga ganesh 2011
16/31
Head Quaters
7-1-27, Ameerpet
Hyderabad, 500 016
India
8/7/2019 durga ganesh 2011
17/31
Employees Motivation
the company attaches great importance to
provide a work culture that allows.
employees the freedom to learn, innovate,
experiment and grow.
An attractive compensation and benefits
plan can look even better Performance
management process flows from an in-
house variant of the balanced
Dr. Reddy's also fosters a sense of
belonging
8/7/2019 durga ganesh 2011
18/31
Reddy labs organization structer
Name Age Since Current Position
Reddy, K. Anji 72 Chairman of the Board
Prasad, G. 50 Vice Chairman of the
Board, Chief Executive
Officer
Vohra, Umang 39 Chief Financial Officer
Mukherjee, Abhijit 52 2010 President - Global
Generics
Chakraborty, Saumen 49 2009 President - Corporate
Reddy, Satish 43 Chief Operating Officer,
Managing Director,
Director
8/7/2019 durga ganesh 2011
19/31
Reddy, Satish 43 Chief Operating Officer,
ManagingDirector, Director
Rao, K. B. Sankara 56 2006 Executive Vice President -
Integrated Product
Development Business
Dholye, Vilas 61 Executive Vice President -
Formulations Manufacturing
Jha, Prabir 43 2007 Senior Vice President, Global
Chief of Human Resources
Patel, Amit 36 2008 Senior Vice President -
North America Generics
business
8/7/2019 durga ganesh 2011
20/31
8/7/2019 durga ganesh 2011
21/31
AWARDS
Dr. Reddy's receives The award for 'Business Leader in the
Pharmaceutical Sector
at the NDTVProfit Business Leadership Awards 2010
MD and COO, SATISH REDDY, received the award from Union
Finance Minister Mr. PRANAB MUKHERJEE on the company'sbehalf.
8/7/2019 durga ganesh 2011
22/31
8/7/2019 durga ganesh 2011
23/31
4. Making the board an ally. Developments such as Sarbanes-Oxley and the
global financial crisis have further distilled corporate boards into the role of
scrutinizing and interrogating management.
8/7/2019 durga ganesh 2011
24/31
campus recruitment
We recruit from premier Business and Technical schools
.
We look for those who dare to dream. Love ambiguity and challenge.
.
programs like Global Internship, your 8 weeks of live project with us
could help you discover where you really want to be at Dr. Reddys.
8/7/2019 durga ganesh 2011
25/31
Recruitment process
Company recruits the people form campus interviews
Return test
interviews
8/7/2019 durga ganesh 2011
26/31
Major Achievements of Dr. Reddy's Laboratories
Dr. Reddy's is the 1st Asia Pacific pharmaceutical company,
outside Japan to be listed on the New York Stock Exchange.
Dr. Reddy's biologics product Reditux (Rituximab) is the firstbiosimilar monoclonal antibody to be developed and launched
anywhere in the world.
8/7/2019 durga ganesh 2011
27/31
Balance sheet
Assets
Current Assets
Cash And Cash Equivalents 7,730,000 5,596,000 186,278
Short Term Investments 3,600,000 530,000 119,315
Net Receivables 12,490,000 14,650,000 187,839
Inventory 13,371,000 13,226,000 279,434
Other Current Assets 5,445,000 5,008,000 96,101
Total Current Assets 42,063,000 39,010,000 868,967
8/7/2019 durga ganesh 2011
28/31
liabilities
Current Liabilities
Accounts Payable 10,754,000 6,619,000 240,503
Short/Current LongTerm Debt
9,271,000 9,683,000 167,606
Other CurrentLiabilities
8,997,000 10,251,000 78,637
Total Current Liabilities 29,022,000 26,553,000 486,746
8/7/2019 durga ganesh 2011
29/31
Top active pharmaceutical ingredients
Ciprofloxacin Hydrochloride
Ramipril Terbinafine HCI
Ibuprofen
Sertaline Hydrochloride
Ranitidine HCI Form 2
8/7/2019 durga ganesh 2011
30/31
8/7/2019 durga ganesh 2011
31/31